Skip to main content
Erschienen in: Osteoporosis International 4/2016

01.04.2016 | Short Communication

Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data

verfasst von: V. Hoffman, F. Xue, B. Gardstein, K. Skerry, C. W. Critchlow, C. Enger

Erschienen in: Osteoporosis International | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

Off-label use of denosumab 60 milligram (mg) injection was assessed within an administrative claims database. The completeness of claims to assess off-label use was investigated with medical record review. Potential denosumab 60 mg off-label use was observed based on claims, but many had evidence of on-label indications based on medical record review.

Introduction

Denosumab 60 mg injection is approved in the USA to treat patients at high fracture risk due to postmenopausal osteoporosis, male osteoporosis, and hormone therapy for the treatment of prostate and breast cancers. Its RANK ligand-inhibiting effect makes it a candidate for the off-label treatment of other conditions mediated by the rate of bone resorption by osteoclasts. To better understand its utilization patterns, we assessed off-label use of denosumab 60 mg within an administrative claims database.

Methods

Definite, probable, and possible denosumab 60 mg users were identified during the early postmarketing period within a claims database of a US healthcare insurer. Medical record review confirmed a sample of these users. Off-label use among definite and probable users and all chart-confirmed users was classified using claims-derived age, dose interval, and diagnosis and treatment received relative to the administration date. Among chart-confirmed users classified as off-label, patient characteristics related to treatment indication were abstracted from medical records to investigate the completeness of claims to study off-label medication use.

Results

Off-label use was identified based on claims in approximately 25 % of definite and probable denosumab 60 mg users and 35 % of chart-confirmed users. Medical record review identified evidence of on-label indications in 81 % of chart-confirmed users classified as off-label in claims.

Conclusions

Many of the off-label denosumab 60 mg users had diagnoses or treatment consistent with on-label indications based on medical record review, suggesting these are under-recorded in claims data. It is warranted to be cautious when using administrative databases to assess off-label medication use.
Literatur
1.
Zurück zum Zitat Lipsy MS, Sharp LK (2001) From idea to market: the drug approval process. J Am Board Fam Pract 14(5):362–367 Lipsy MS, Sharp LK (2001) From idea to market: the drug approval process. J Am Board Fam Pract 14(5):362–367
3.
Zurück zum Zitat Platt R, Madre L, Reynolds R et al (2008) Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 17(12):1175–82CrossRefPubMed Platt R, Madre L, Reynolds R et al (2008) Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 17(12):1175–82CrossRefPubMed
4.
Zurück zum Zitat Czaja AS, Valuck R (2012) Off‐label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf 21(9):997–1004CrossRefPubMed Czaja AS, Valuck R (2012) Off‐label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf 21(9):997–1004CrossRefPubMed
5.
Zurück zum Zitat Gleason PP, Walters C, Heaton AH et al (2007) Telithromycin: the perils of hasty adoption and persistence of off‐label prescribing. J Manag Care Pharm 13(5):420–425PubMed Gleason PP, Walters C, Heaton AH et al (2007) Telithromycin: the perils of hasty adoption and persistence of off‐label prescribing. J Manag Care Pharm 13(5):420–425PubMed
6.
Zurück zum Zitat (2012) Prolia® (denosumab) prescribing information, Amgen. Revised September. (2012) Prolia® (denosumab) prescribing information, Amgen. Revised September.
7.
Zurück zum Zitat McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821–831CrossRefPubMed McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821–831CrossRefPubMed
8.
Zurück zum Zitat Ellis GK, Bone HG, Chiebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875–4882CrossRefPubMed Ellis GK, Bone HG, Chiebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30):4875–4882CrossRefPubMed
10.
Zurück zum Zitat Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefPubMed Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefPubMed
12.
13.
Zurück zum Zitat Orwoll E, Teglbjærg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161–9. doi:10.1210/jc.2012-1569 CrossRefPubMed Orwoll E, Teglbjærg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161–9. doi:10.​1210/​jc.​2012-1569 CrossRefPubMed
14.
Zurück zum Zitat Romas E (2009) Clinical applications of RANK‐ligand inhibition. Intern Med J 39(2):110–116CrossRefPubMed Romas E (2009) Clinical applications of RANK‐ligand inhibition. Intern Med J 39(2):110–116CrossRefPubMed
16.
Zurück zum Zitat XGEVA® (denosumab) prescribing information, Amgen. Revised January 2013 XGEVA® (denosumab) prescribing information, Amgen. Revised January 2013
17.
Zurück zum Zitat Hoffman V, Xue F, Gardstein B et al (2014) Development and evaluation of an algorithm to identify users of Prolia® during the early postmarketing period using health insurance claims data. Pharmacoepidemiol Drug Saf 23(9):993–998. doi:10.1002/pds.3680 CrossRefPubMed Hoffman V, Xue F, Gardstein B et al (2014) Development and evaluation of an algorithm to identify users of Prolia® during the early postmarketing period using health insurance claims data. Pharmacoepidemiol Drug Saf 23(9):993–998. doi:10.​1002/​pds.​3680 CrossRefPubMed
18.
Zurück zum Zitat National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC
19.
Zurück zum Zitat Xue F, Ma H, Stehman-Breen C et al (2013) For the denosumab global safety assessment team. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia®(denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf 22(10):1107–14. doi:10.1002/pds.3477 PubMedPubMedCentral Xue F, Ma H, Stehman-Breen C et al (2013) For the denosumab global safety assessment team. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia®(denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf 22(10):1107–14. doi:10.​1002/​pds.​3477 PubMedPubMedCentral
Metadaten
Titel
Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data
verfasst von
V. Hoffman
F. Xue
B. Gardstein
K. Skerry
C. W. Critchlow
C. Enger
Publikationsdatum
01.04.2016
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 4/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3402-9

Weitere Artikel der Ausgabe 4/2016

Osteoporosis International 4/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.